BLGO vs. ARQ, VGAS, AMTX, LODE, ZTEK, TSE, ALTO, ORGN, LNZA, and LOOP
Should you be buying BioLargo stock or one of its competitors? The main competitors of BioLargo include ARQ (ARQ), Verde Clean Fuels (VGAS), Aemetis (AMTX), Comstock (LODE), Zentek (ZTEK), Trinseo (TSE), Alto Ingredients (ALTO), Origin Materials (ORGN), LanzaTech Global (LNZA), and Loop Industries (LOOP). These companies are all part of the "chemicals" industry.
BioLargo vs. Its Competitors
BioLargo (NASDAQ:BLGO) and ARQ (NASDAQ:ARQ) are both small-cap chemicals companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.
BioLargo has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, ARQ has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500.
ARQ has a net margin of -1.30% compared to BioLargo's net margin of -11.45%. ARQ's return on equity of -0.71% beat BioLargo's return on equity.
BioLargo has higher earnings, but lower revenue than ARQ. ARQ is trading at a lower price-to-earnings ratio than BioLargo, indicating that it is currently the more affordable of the two stocks.
0.0% of BioLargo shares are owned by institutional investors. Comparatively, 18.5% of ARQ shares are owned by institutional investors. 19.3% of BioLargo shares are owned by company insiders. Comparatively, 23.9% of ARQ shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, ARQ had 1 more articles in the media than BioLargo. MarketBeat recorded 2 mentions for ARQ and 1 mentions for BioLargo. ARQ's average media sentiment score of 0.43 beat BioLargo's score of 0.00 indicating that ARQ is being referred to more favorably in the news media.
ARQ has a consensus price target of $9.00, indicating a potential upside of 56.25%. Given ARQ's stronger consensus rating and higher probable upside, analysts clearly believe ARQ is more favorable than BioLargo.
Summary
ARQ beats BioLargo on 13 of the 17 factors compared between the two stocks.
Get BioLargo News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLGO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BLGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLargo Competitors List
Related Companies and Tools
This page (NASDAQ:BLGO) was last updated on 7/3/2025 by MarketBeat.com Staff
